Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial
The addition of anlotinib to docetaxel was characterized by a manageable safety profile and also resulted in a significant improvement in progression-free survival among patients with advanced NSCLC who had previously failed platinum-based chemotherapy (ClinicalTrials.gov identifier NCT03726736).
Authors
- Fen Lan
- Chuangzhou Rao (ORCID: https://orcid.org/0000-0003-1101-5120)
- Hong Wei
- Jun Chen (ORCID: https://orcid.org/0000-0003-2164-6970)
- Xin‐Mei Yang
- Dan Zhu (ORCID: https://orcid.org/0000-0002-1800-5737)
- Qunyi Guo
- Yong Fang (ORCID: https://orcid.org/0000-0002-0588-2116)
- Liqin Lu (ORCID: https://orcid.org/0000-0001-7786-5035)
- Yonghui Wang (ORCID: https://orcid.org/0000-0002-3172-2458)
- Jiawei Shou
- Hongming Pan
Institutions
- Wenzhou Medical University (CN)
- Sir Run Run Shaw Hospital (CN)
- Jiaxing University (CN)
- Zhejiang Cancer Hospital (CN)
- Ningbo No. 2 Hospital (CN)
- Lishui Central Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- First Hospital of Jiaxing (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Zhejiang Taizhou Hospital (CN)
- Jinhua Central Hospital (CN)
- Hangzhou Cancer Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1002/cncr.35822
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Chinese Society of Clinical Oncology
- National Key Research and Development Program of China
- Medical Science and Technology Project of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
- Science and Technology Program of Zhejiang Province